SL Science Holding Ltd(SLBT)

Biotechnology · Taipei, NY

$1.52-0.07 (-4.40%)

Delayed quote: Oct 6, 2026, 4:00 PM EDT

EBITDA Yield: N/A

Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.

The EBITDA yield is N/A as of 2026-10-06T21:29:00.453Z.

Stored calculation inputs

Calculation as of: 2026-10-06T21:29:00.453Z.

Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.

TTM operating EBITDA: N/A
Quote market capitalization: 852,354,826
Total debt · period ending 2025-12-31: 213,405
Cash · period ending 2025-12-31: 1,258,616

FMP input reference: 680db3c2305e98602fe5277f15244516f30a0ab53cbf5830e5b41f5092839f7c

EV/EBITDA|Earnings Yield|OCF Yield|FCF Yield|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

SLBT EBITDA Yield Metrics

EBITDA YIELD

N/A

SLBT Competitors' EBITDA Yield

SLBT

SL Science Holding Ltd

Current

Market Cap

$852.35M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

RIGL

Rigel Pharmaceuticals, Inc.

vs SLBT

Market Cap

$853.13M

EBITDA Yield

10.78%

TTM Avg

17.19%

3Y Avg

13.36%

5Y Avg

13.36%

ALMS

Alumis Inc.

vs SLBT

Market Cap

$855.38M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

QDEL

QuidelOrtho Corporation

vs SLBT

Market Cap

$857.16M

EBITDA Yield

N/A

TTM Avg

5.29%

3Y Avg

9.22%

5Y Avg

17.53%

PACB

Pacific Biosciences of California, Inc.

vs SLBT

Market Cap

$838.62M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

BBNX

Beta Bionics, Inc.

vs SLBT

Market Cap

$838.16M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

SIBN

SI-BONE, Inc.

vs SLBT

Market Cap

$867.03M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ODTX

Odyssey Therapeutics, Inc.

vs SLBT

Market Cap

$870.81M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

GLUE

Monte Rosa Therapeutics, Inc.

vs SLBT

Market Cap

$833.81M

EBITDA Yield

N/A

TTM Avg

3.15%

3Y Avg

3.15%

5Y Avg

3.15%

SGP

SpyGlass Pharma, Inc. Common Stock

vs SLBT

Market Cap

$828.48M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	EBITDA YIELD	TTM	3Y	5Y
SL Science Holding Ltd (SLBT)	$852.35M	N/A	N/A	N/A	N/A
Rigel Pharmaceuticals, Inc. (RIGL)vs ›	$853.13M	10.78%	17.19%	13.36%	13.36%
Alumis Inc. (ALMS)vs ›	$855.38M	N/A	N/A	N/A	N/A
QuidelOrtho Corporation (QDEL)vs ›	$857.16M	N/A	5.29%	9.22%	17.53%
Pacific Biosciences of California, Inc. (PACB)vs ›	$838.62M	N/A	N/A	N/A	N/A
Beta Bionics, Inc. (BBNX)vs ›	$838.16M	N/A	N/A	N/A	N/A
SI-BONE, Inc. (SIBN)vs ›	$867.03M	N/A	N/A	N/A	N/A
Odyssey Therapeutics, Inc. (ODTX)vs ›	$870.81M	N/A	N/A	N/A	N/A
Monte Rosa Therapeutics, Inc. (GLUE)vs ›	$833.81M	N/A	3.15%	3.15%	3.15%
SpyGlass Pharma, Inc. Common Stock (SGP)vs ›	$828.48M	N/A	N/A	N/A	N/A

EBITDA Yield Formula & Definition

EBITDA Yield = TTM EBITDA / Enterprise Value

EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

EBITDA Yield: N/A

SLBT EBITDA Yield Metrics

SLBT Competitors' EBITDA Yield

EBITDA Yield Formula & Definition

Related Metrics